Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Study of Human Microbiota in Healthy and Pathological Conditions (MicroSP)

2. mars 2018 oppdatert av: Istituto Ortopedico Galeazzi

The aim of the present study is to characterize the bacterial composition (microbiota) colonizing to the human body in different physio - pathological conditions (lifestyle, motor activity, surgical operations, probiotic and prebiotic consumption, antibiotic therapies, chemotherapeutic therapies), nervous and musculoskeletal diseases, gastrointestinal and metabolic disorders , oral and vaginal diseases, etc.). In particular, they will be investigate:

  • the changes in the bacterial abundance
  • the potential microbial interactions with the human host
  • the microbial networks describing on the bacterial interactions within a specific composition of the human microbiota

Studieoversikt

Status

Ukjent

Intervensjon / Behandling

Detaljert beskrivelse

The main objective of this study is to deepen the knowledge about the bacterial communities associated to the human organism. In particular, the present study aims to evaluate how the microbiota (intestinal, cutaneous, vaginal, nasal, bronchial, breast milk, salivary, oral, etc.) is subject to quantitative and qualitative changes consequently to different events involving the human host. The project trys to highlight which microorganisms may be involved in the onset or progression of certain pathological condition, as well as to identify which bacterial genera can be more subject to variations due to specific non-pathological events.

Secondary objectives of this study are:

  • To define a "healthy microbiome", that is to understand which are the main bacteria that commonly compose the human microbiome in physiological conditions, differentiating it from that present in certain pathological conditions.
  • To characterize the physiological effects that bacterial changes of the human microbiota have on the host.
  • To evaluate whether the use of probiotics, prebiotics, dietary and nutritional factors, cosmetics, and oral, nasal, vaginal, or pharmacological therapies of any kind can influence the microbial network of the human microbiota associated to different body districts.

Studietype

Observasjonsmessig

Registrering (Forventet)

30

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiesteder

    • MI
      • Milan, MI, Italia, 20161
        • IRCCS Istituto Ortopedico Galeazzi

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Ja

Kjønn som er kvalifisert for studier

Alle

Prøvetakingsmetode

Ikke-sannsynlighetsprøve

Studiepopulasjon

For each cohoort 15 healthy subjects will be enrolled (controls), for a total of 90 subjects.

The study involves the recruitment of 180 subjects (90 pathological and 90 healthy and recruited

Beskrivelse

Inclusion Criteria:

  • subjects suffering from neurological/behavioral diseases;
  • subjects suffering of bone diseases;
  • subjects affected of dysmetabolic / or endocrine disorders;
  • subjects with physical activities at a competitive level;
  • subjects affected of gastrointestinal disorders;
  • subjects with prolonged antibiotic therapies and undergoing surgery

Exclusion Criteria:

  • no use of probiotics in the month prior the sampling;
  • no use of antibiotics in the month prior the sampling;
  • no consumption of yogurt in the month prior the sampling;

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

Kohorter og intervensjoner

Gruppe / Kohort
Intervensjon / Behandling
Neurological and behavioral disorders
Subjects with neurological or behavioral disorders such as Tourette syndrome are enrolled.
To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
Andre navn:
  • Probiotics, dietary factors, cosmetics and adjuvants
Subjects affected by bone diseases
Subjects affected by bone diseases such as infective osteomyelitis or osteoporosis are enrolled.
To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
Andre navn:
  • Probiotics, dietary factors, cosmetics and adjuvants
Dysmetabolic and/or endocrine disorders
Patients with endocrine disorders, such as thyroid disfunctions, or with metabolic disorders, including diabetes mellitus,are enrolled.
Subjects performing agonistic activity
Subjects performing physical activity at agonistic level are enrolled.
Gastroenteric disorders
Subjects affected by gastric and/or enteric disorders are enrolled.
Prolonged antibiotic therapy
Patients subjected to prolonged antibiotic therapies and undergone a variety of surgical procedures are enrolled.
To evaluate the effects of a specific event (i.e. surgical operation) or therapy (i.e antibiotic treatment) over time;
Andre navn:
  • Probiotics, dietary factors, cosmetics and adjuvants
Healthy subjects
Subjects without any known ongoing disease are enrolled.

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Bacterial abundances calculated by mean of Operational Taxonomic Unit (OTU) count
Tidsramme: Up to 24 weeks
It is a measure of the bacterial amount
Up to 24 weeks

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Chao's indices estimated on the total OTU amount
Tidsramme: Up to 24 weeks
It is a measure of bacterial diversity
Up to 24 weeks
Simpson's index (D) estimated on the total OTU amount
Tidsramme: Up to 24 weeks
It is a measure of bacterial diversity
Up to 24 weeks
Shannon's index estimated on the total OTU amount
Tidsramme: Up to 24 weeks
It is a measure of bacterial diversity
Up to 24 weeks
The OTU abundances will be used to calculate an adjacency matrix based on the Spearman's correlation coefficient (rs) among different bacterial genus
Tidsramme: up to 24 weeks
It is a measure of strength of linear association between different bacterial genera
up to 24 weeks

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Etterforskere

  • Hovedetterforsker: Lorenzo Drago, Prof., IRCCS Galeazzi Orthopedic Institute, Milan, Italy

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

12. juni 2017

Primær fullføring (Faktiske)

31. juli 2017

Studiet fullført (Forventet)

31. desember 2019

Datoer for studieregistrering

Først innsendt

15. februar 2018

Først innsendt som oppfylte QC-kriteriene

2. mars 2018

Først lagt ut (Faktiske)

9. mars 2018

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

9. mars 2018

Siste oppdatering sendt inn som oppfylte QC-kriteriene

2. mars 2018

Sist bekreftet

1. februar 2018

Mer informasjon

Begreper knyttet til denne studien

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Kliniske studier på Mikrobiell kolonisering

Kliniske studier på Antibiotic therapy

3
Abonnere